论文部分内容阅读
肝纤维化及其终末病变肝硬化已严重危害全球人类健康,虽然慢性肝病的治疗手段和抗肝纤维化药物的研究已取得了很大进展,肝移植依然是最有效的治疗方案,但器官的紧缺却是一个现实问题。目前寻找有效的干预手段进行抗肝纤维化治疗已越来越受到大家的关注。近些年,大量基础及临床研究均证实在一定条件下利用骨髓间充质干细胞(MSCs)可以抑制肝星状细胞活化诱导其凋亡,实现肝纤维化逆转。随着干细胞技术的快速发展,基于骨髓间充质干细胞(MSCs)的细胞疗法在肝纤维化治疗领域的研究与应用已成为一个充满生命力的新方向。本文将对肝纤维化及基于MSCs的治疗机制进展及其应用进行综述。
Liver fibrosis and its terminal lesion Liver cirrhosis has seriously endanger global human health. Although the treatment of chronic liver disease and anti-liver fibrosis drugs have made great progress, liver transplantation remains the most effective treatment, but the organ The shortage is a real problem. Currently looking for effective interventions for anti-fibrosis treatment has been more and more everyone’s attention. In recent years, a large number of basic and clinical studies have confirmed that under certain conditions using bone marrow mesenchymal stem cells (MSCs) can inhibit activation of hepatic stellate cells to induce apoptosis and achieve reversal of liver fibrosis. With the rapid development of stem cell technology, the research and application of cell therapy based on bone marrow mesenchymal stem cells (MSCs) in the treatment of liver fibrosis has become a new direction with vitality. This article reviews the progress of liver fibrosis and MSCs-based therapeutic mechanisms and their applications.